Moderna wins FDA OK to widen use of RSV vaccine

The Food and Drug Administration has approved wider use of Moderna’s respiratory syncytial virus vaccine in a boost for a company that’s been negatively impacted by the recent leadership changes atop U.S. public health agencies.  

The shot, dubbed mResvia, was cleared on Thursday for adults aged 18 to 59 who are at high risk for increased risk of RSV-related disease. Prior to the label expansion, Moderna’s shot was only available to adults 60 or older. 

“RSV poses a serious health risk to adults with certain chronic conditions, and today’s approval marks an important step forward in our ability to protect additional populations from severe illness from RSV,” Moderna CEO Stéphane Bancel said in a statement. 

Read Full Article Here